EVELO BIOSCIENCES INC's ticker is EVLO and the CUSIP is 299734103. A total of 68 filers reported holding EVELO BIOSCIENCES INC in Q1 2022. The put-call ratio across all filers is 3.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $51,000 | -48.0% | 15,079 | -6.6% | 0.00% | – |
| Q4 2021 | $98,000 | -16.2% | 16,140 | -2.9% | 0.00% | -100.0% |
| Q3 2021 | $117,000 | -50.0% | 16,623 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $234,000 | +62.5% | 17,018 | +26.8% | 0.00% | 0.0% |
| Q1 2021 | $144,000 | +2.9% | 13,422 | +15.5% | 0.00% | 0.0% |
| Q4 2020 | $140,000 | +122.2% | 11,621 | -2.8% | 0.00% | – |
| Q3 2020 | $63,000 | +50.0% | 11,955 | +39.5% | 0.00% | – |
| Q2 2020 | $42,000 | +35.5% | 8,568 | +5.3% | 0.00% | – |
| Q1 2020 | $31,000 | -11.4% | 8,137 | -5.5% | 0.00% | – |
| Q4 2019 | $35,000 | -34.0% | 8,608 | -0.8% | 0.00% | – |
| Q3 2019 | $53,000 | -32.1% | 8,680 | -0.7% | 0.00% | – |
| Q2 2019 | $78,000 | +11.4% | 8,741 | -0.6% | 0.00% | – |
| Q1 2019 | $70,000 | -40.7% | 8,791 | -3.2% | 0.00% | – |
| Q4 2018 | $118,000 | +174.4% | 9,077 | +155.2% | 0.00% | – |
| Q3 2018 | $43,000 | +4.9% | 3,557 | +1.8% | 0.00% | – |
| Q2 2018 | $41,000 | – | 3,494 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 484,953 | $1,823,000 | 4.61% |
| Flagship Pioneering Inc. | 18,233,403 | $68,558,000 | 3.21% |
| HARBOURVEST PARTNERS LLC | 1,763,505 | $6,622,000 | 3.20% |
| Alphabet Inc. | 1,060,495 | $3,982,000 | 0.26% |
| Larson Financial Group LLC | 20,042 | $75,000 | 0.05% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 133,500 | $501,000 | 0.01% |
| CREDIT SUISSE AG/ | 1,500,117 | $5,633,000 | 0.01% |
| FMR LLC | 3,220,853 | $12,094,000 | 0.00% |
| VICTORY CAPITAL MANAGEMENT INC | 177,856 | $668,000 | 0.00% |
| Legal & General Group Plc | 1,522 | $6,000 | 0.00% |